BRAFV600E mutation is correlated with the biological behaviors of papillary thyroid microcarcinoma: a Meta-analysis
10.3760/cma.j.issn.2095-2848.2018.03.012
- VernacularTitle:BRAFV600E突变与甲状腺微小乳头状癌生物学行为关联的Meta分析
- Author:
Jingjing ZHANG
1
;
Yanping ZHAO
;
Xiong XIAO
;
Xinhua WANG
;
Zhanfei DONG
Author Information
1. 新疆医科大学附属肿瘤医院核医学科
- Keywords:
Thyroid neoplasms;
Proto-oncogene proteins B-raf;
Mutation;
Meta analysis
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2018;38(3):199-204
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the association between V-raf murine sarcoma viral oncogene homolog B1 (BRAF)V600E mutation and biological behaviors of papillary thyroid microcarcinoma (PTMC).Methods Published papers about the association between BRAFV600E mutation and aggressiveness of PTMC from January 2011 to January 2016 were collected using databases of Wanfang,VIP,China National Knowl-edge Infrastructure (CNKI),PubMed,Embase and Cochrane library.The key words were "PTMC","papillary thyroid microcarcinoma"," thyroid microcarcinoma"," micropapillary thyroid carcinoma"," BRAF".The languages were restricted to English and Chinese.Meta-analysis was performed with RevMan 5.3 software.Results Eighteen studies involving 2 938 patients were included.A total of 1 536 patients showed BRAFV600E mutation-positive results,and 1 402 patients were with wild type.The average prevalence of the BRAFV600E mutation was 52.3％.The BRAFV600E mutation was associated with the multifocality (odds ratio (OR)=1.37,95％ CI:1.11-1.67),extrathyroid extension(OR=2.25,95％ CI:1.31-3.86),lymph node metastases (OR =3.05,95％ CI:1.60-5.79),advanced stage (TNM Ⅲ + Ⅳ;OR =1.99,95％ CI:1.54-2.57),recurrence(OR=2.92,95％ CI:1.84-4.65),male patients(OR=1.70,95％ CI:1.35-2.14) and tumor diameter ＞5 mm(OR=1.62,95％ CI:1.29～2.04)of PTMC.There was no significant association between BRAFV600E mutation and age or distant metastases.Conclusion BRAFV600E mutation is a risk factor for aggressive behaviors of PTMC.
